LLY

977.55

-2.54%↓

JNJ

238.59

-2.76%↓

ABBV

231.29

-1.91%↓

NVS

160.78

-2.45%↓

AZN

197.28

-2.62%↓

LLY

977.55

-2.54%↓

JNJ

238.59

-2.76%↓

ABBV

231.29

-1.91%↓

NVS

160.78

-2.45%↓

AZN

197.28

-2.62%↓

LLY

977.55

-2.54%↓

JNJ

238.59

-2.76%↓

ABBV

231.29

-1.91%↓

NVS

160.78

-2.45%↓

AZN

197.28

-2.62%↓

LLY

977.55

-2.54%↓

JNJ

238.59

-2.76%↓

ABBV

231.29

-1.91%↓

NVS

160.78

-2.45%↓

AZN

197.28

-2.62%↓

LLY

977.55

-2.54%↓

JNJ

238.59

-2.76%↓

ABBV

231.29

-1.91%↓

NVS

160.78

-2.45%↓

AZN

197.28

-2.62%↓

Inicio・Lista de Acciones・Novavax Inc

Novavax Inc

Abierto

SectorSalud

9.78 -2.3

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.5

Máximo

10.01

Métricas clave
By Trading Economics
Ingresos	220M 18M
Ventas	77M 147M
P/B Media del Sector	5.03 66.845
BPA	0.11
Margen de beneficio	11.912
Empleados	952
EBITDA	217M 26M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+33.51% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	122M 1.6B
Apertura anterior	12.08
Cierre anterior	9.78

Noticias sobre sentimiento de mercado

By Acuity

93%

6 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

5.692 / 6.039 Soporte y Resistencia

Novavax Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 17:06 UTC

Principales Movimientos del Mercado

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31 mar 2025, 14:19 UTC

Principales Movimientos del Mercado

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

19 may 2025, 14:30 UTC

Principales Noticias

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

19 may 2025, 13:27 UTC

Principales Noticias

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

8 may 2025, 17:55 UTC

Ganancias

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 may 2025, 15:12 UTC

Ganancias

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

28 abr 2025, 17:04 UTC

Ganancias

Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot. -- Barrons.com

Comparación entre iguales

Cambio de precio

Novavax Inc Esperado

Precio Objetivo

By TipRanks

33.51% repunte

Estimación a 12 meses

Media 12.67 USD 33.51%

Máximo 19 USD

Mínimo 7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novavax Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Novavax Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.692 / 6.039Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

6 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.